Cadrenal Therapeutics, Inc. financial data

Symbol
CVKD on Nasdaq
Location
822 A1 A North, Suite 306, Ponte Vedra, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 372 % -35.9%
Debt-to-equity 36.7 % +77%
Return On Equity -280 % -95.5%
Return On Assets -204 % -72.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.08M shares +25.1%
Common Stock, Shares, Outstanding 2.06M shares +66.8%
Entity Public Float 4.01M USD -37.4%
Common Stock, Value, Issued 2.06K USD +66.9%
Weighted Average Number of Shares Outstanding, Basic 2.04M shares +85.1%
Weighted Average Number of Shares Outstanding, Diluted 2.04M shares +85.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.97M USD +64.2%
General and Administrative Expense 9.7M USD +97.3%
Operating Income (Loss) -14.7M USD -84.7%
Nonoperating Income (Expense) 289K USD -14.5%
Net Income (Loss) Attributable to Parent -14.4M USD -89.1%
Earnings Per Share, Basic -8 USD/shares +41.4%
Earnings Per Share, Diluted -8 USD/shares +41.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.86M USD -11.5%
Assets, Current 4.08M USD -12.7%
Property, Plant and Equipment, Net 5.73K USD +604%
Operating Lease, Right-of-Use Asset 2.2K USD -91.8%
Other Assets, Noncurrent 2.17K USD -42.9%
Assets 4.09M USD -12.6%
Accounts Payable, Current 614K USD +23.6%
Employee-related Liabilities, Current 967K USD +62.1%
Accrued Liabilities, Current 739K USD -3.82%
Liabilities, Current 1.35M USD +6.77%
Operating Lease, Liability, Noncurrent 2.23K USD
Liabilities 1.35M USD +6.77%
Retained Earnings (Accumulated Deficit) -35.9M USD -66.8%
Stockholders' Equity Attributable to Parent 2.73M USD -19.9%
Liabilities and Equity 4.09M USD -12.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.65M USD -153%
Net Cash Provided by (Used in) Financing Activities 1.97M USD
Net Cash Provided by (Used in) Investing Activities -3.25K USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 2.06M shares +66.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.86M USD -11.5%
Deferred Tax Assets, Valuation Allowance 4.74M USD +118%
Deferred Tax Assets, Gross 4.74M USD +117%
Operating Lease, Liability 2.23K USD -91.8%
Depreciation 6.73K USD +225%
Payments to Acquire Property, Plant, and Equipment 3.25K USD
Lessee, Operating Lease, Liability, to be Paid 2.22K USD -0.58%
Operating Lease, Liability, Current 2.23K USD -91.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 22.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 22.7K USD +1.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 132 USD -94.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 22.3K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.75M USD +150%
Preferred Stock, Shares Authorized 7.5M shares 0%
Additional Paid in Capital 38.7M USD +54.9%
Preferred Stock, Shares Outstanding 7.5M shares
Deferred Tax Assets, Net of Valuation Allowance 2.56M USD
Share-based Payment Arrangement, Expense 2.38M USD +213%
Interest Expense 41.6K USD +69.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%